Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2009 1
2010 1
2011 1
2012 4
2013 1
2014 1
2015 3
2016 3
2017 4
2018 10
2019 13
2020 20
2021 19
2022 13
2023 6
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy.
Louis R, Harrison TW, Chanez P, Menzella F, Philteos G, Cosio BG, Lugogo NL, de Luiz G, Burden A, Adlington T, Keeling N, Kwiatek J, Garcia Gil E; ANDHI Study Investigators. Louis R, et al. Among authors: menzella f. J Allergy Clin Immunol Pract. 2023 Jun;11(6):1759-1770.e7. doi: 10.1016/j.jaip.2023.03.009. Epub 2023 Mar 21. J Allergy Clin Immunol Pract. 2023. PMID: 36948488 Free article.
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
Harrison TW, Chanez P, Menzella F, Canonica GW, Louis R, Cosio BG, Lugogo NL, Mohan A, Burden A, McDermott L, Garcia Gil E, Zangrilli JG; ANDHI study investigators. Harrison TW, et al. Among authors: menzella f. Lancet Respir Med. 2021 Mar;9(3):260-274. doi: 10.1016/S2213-2600(20)30414-8. Epub 2020 Dec 22. Lancet Respir Med. 2021. PMID: 33357499 Clinical Trial.
Targeting eosinophils: severe asthma and beyond.
Caminati M, Menzella F, Guidolin L, Senna G. Caminati M, et al. Among authors: menzella f. Drugs Context. 2019 Jul 23;8:212587. doi: 10.7573/dic.212587. eCollection 2019. Drugs Context. 2019. PMID: 31391853 Free PMC article. Review.
Long-term effectiveness of benralizumab in severe eosinophilic asthma patients treated for 96-weeks: data from the ANANKE study.
Vultaggio A, Aliani M, Altieri E, Bracciale P, Brussino L, Caiaffa MF, Cameli P, Canonica GW, Caruso C, Centanni S, D'Amato M, De Michele F, Del Giacco S, Di Marco F, Menzella F, Pelaia G, Rogliani P, Romagnoli M, Schino P, Senna G, Benci M, Boarino S, Schroeder JW. Vultaggio A, et al. Among authors: menzella f. Respir Res. 2023 May 20;24(1):135. doi: 10.1186/s12931-023-02439-w. Respir Res. 2023. PMID: 37210543 Free PMC article.
Pharmacologicaltreatment of COVID-19: lights and shadows.
Menzella F, Biava M, Barbieri C, Livrieri F, Facciolongo N. Menzella F, et al. Drugs Context. 2020 May 19;9:2020-4-6. doi: 10.7573/dic.2020-4-6. eCollection 2020. Drugs Context. 2020. PMID: 32499832 Free PMC article. Review.
Tailored therapy for severe asthma.
Menzella F, Lusuardi M, Galeone C, Zucchi L. Menzella F, et al. Multidiscip Respir Med. 2015 Jan 16;10(1):1. doi: 10.1186/2049-6958-10-1. eCollection 2015. Multidiscip Respir Med. 2015. PMID: 25671117 Free PMC article. Review.
95 results